Latest H. Lundbeck A/S Stories

2011-05-11 06:00:00

EVANSTON, Ill., May 11, 2011 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners. Druid BioVentures, Genesys Capital, PathoCapital, Lundbeck, Takeda Ventures, Inc. and Shire also participated in the round. Naurex will use the proceeds from the Series A financing primarily for...

2010-12-16 01:00:00

LA JOLLA, Calif., Dec. 16, 2010 /PRNewswire/ -- Zenobia Therapeutics, Inc. (Zenobia) the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S (Lundbeck) utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery...

2010-06-15 05:00:00

MINNEAPOLIS, June 15 /PRNewswire/ -- Orasi Medical® today announced that it has entered an agreement with H. Lundbeck A/S (Lundbeck) to study the effect of Lundbeck central nervous system (CNS) compounds on the human brain. (Logo: http://photos.prnewswire.com/prnh/20100615/CG19932LOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100615/CG19932LOGO) With the average time to bring a CNS drug to market exceeding 12 years - and only 7 percent of neurological drugs making...

2009-10-09 08:00:00

DEERFIELD, Ill., Oct. 9 /PRNewswire/ -- The Huntington's Disease Society of America (HDSA) recognized Lundbeck last night with the Marjorie Guthrie Leadership Award for the company's steadfast commitment to the Huntington's disease (HD) community and for making a meaningful contribution to patients and families impacted by HD across the country. Lundbeck was honored at the 13th Annual HDSA Guthrie Awards Dinner celebration in New York. The award is bestowed annually to a corporate...

2009-07-10 08:15:00

NEW YORK, July 10, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and its wholly-owned subsidiary, Forest Laboratories Holdings, Ltd. (collectively, "Forest"), and H. Lundbeck A/S ("Lundbeck") announced today that they have entered into a settlement agreement with Sun Pharmaceutical Industries Ltd. ("Sun Pharma", a reference that includes its 100% subsidiaries) and Caraco Pharmaceutical Laboratories, Ltd. ("Caraco"), regarding pending patent infringement disputes...

2008-07-15 06:00:57

Clinical Data, Inc. (NASDAQ:CLDA) a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced today that its Cogenics(R) division has entered into a Scientific Research & Development Agreement with H. Lundbeck A/S to support its ongoing clinical studies with genotyping solutions on a global basis. Lundbeck is an international pharmaceutical company engaged in the research and development, production,...

Word of the Day
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.